Myeloma expert Dr. Betsy O’Donnell reviews the terms that define myeloma treatment response, such as complete remission (CR) and partial remission (PR). Dr. O’Donnell goes on to discuss the new tools that are being used to monitor treatment effectiveness, including MRD (minimal residual disease).
Dr. Betsy O'Donnell is Assistant Professor of Medicine at the Dana-Farber Cancer Institute specializing in Plasma Cell Disorders.
Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to fortify cancer patients and care partners with the knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them in receiving the best, most personalized care available to ensure they have the best possible outcome. Subscribe now to receive the latest news on cancer treatment and research: [ Ссылка ]
How Is Myeloma Treatment Response Measured?
Теги
Dr. Irene GhobrialDr. Omar NadeemDr. Betsy O’DonnellDana-Farber Cancer InstituteMyelomatreatment approachespersonalized therapytargeted therapiesimmunotherapiesCAR-TSPEPSerum Protein Electrophoresisbone marrow biopsyFISHcytogeneticsM-spikeM-proteinrelapserefractorystem cell transplantremissionMRDminimal residual diseasemultiple myelomamyeloma treatmentmyeloma researchlenalidomiderevlimidcomplete remissionmyeloma remission
